Protecting the World from Pertussis and Other Re-Emerging Global Diseases
BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure. The company currently distributes a portfolio of vaccines through an established global commercial network and continues to expand its operations across continents.
BioNet Key facts
3 licensed
recombinant pertussis vaccines
200+ collaborators
sharing their passion for vaccines
25+ years’ experience in vaccine development, manufacturing and commercialization
20+ clinical trials experience
10+ mRNA candidates
Latest News
BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation
Lyon, France & Bangkok, Thailand – January 17, 2025 – BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in collaboration with LTS Lohmann Therapie-Systeme AG, this recognition underscores BioNet’s contributions to mRNA vaccine technologies and their transformative potential to improve global health.
LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition
Andernach – LTS, a leading pharmaceutical technology company, and BioNet, a biotech manufacturer specializing in genetically engineered vaccines, announced today their selection as a Concept Stage winner of the #PatchForwardPrize, a $50 million challenge by BARDA to advance microneedle patch-based RNA vaccine technologies. This recognition highlights the groundbreaking potential of their collaboration in mRNA vaccine development and delivery.
The Patch Forward Prize, part of the Project NextGen initiative led by the Biomedical Advanced Research and Development Authority (BARDA), aims to accelerate next-generation vaccine technologies.
BARDA announces $8 million in awards to advance microneedle patch-based RNA vaccine development as part of the Patch Forward Prize
Today, the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), announced four winners of the Concept Stage of the Patch Forward Prize. Each winner received $2 million to advance innovative microneedle patch-based technologies for RNA-based COVID-19, seasonal influenza, and pandemic influenza vaccines that enable easier and faster vaccine distribution and administration, improving rapid response capabilities and the nation’s health security.